Pharmaceuticals (Oct 2021)

Mechanistic Insights into Binding of Ligands with Thiazolidinedione Warhead to Human Histone Deacetylase 4

  • Markus Schweipert,
  • Niklas Jänsch,
  • Neha Upadhyay,
  • Kalpana Tilekar,
  • Ewelina Wozny,
  • Sidra Basheer,
  • Eva Wurster,
  • Marlene Müller,
  • Ramaa C S,
  • Franz-Josef Meyer-Almes

DOI
https://doi.org/10.3390/ph14101032
Journal volume & issue
Vol. 14, no. 10
p. 1032

Abstract

Read online

Recently, we have reported that non-hydroxamate thiazolidinedione (TZD) analogs are capable of inhibiting human deacetylase 4 (HDAC4). This study aims at the dissection of the molecular determinants and kinetics of the molecular recognition of TZD ligands by HDAC4. For this purpose, a structure activity relationship analysis of 225 analogs was combined with a comprehensive study of the enzyme and binding kinetics of a variety of HDAC4 mutant variants. The experimental data were rationalized by docking to the two major conformations of HDAC4. TZD ligands are competitive inhibitors and bind via a two-step mechanism involving principal molecular recognition and induced fit. The residence time of 24 g is (34 ± 3) min and thus much larger than that of the canonical pan-HDAC inhibitor SAHA ((5 ± 2) min). Importantly, the binding kinetics can be tuned by varying the structure of the CAP group.

Keywords